ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

Company Overview

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.60 to $0.60
• 52-Week Range: $0.48 to $25.44
• Volume: N/A
• Average Volume: 122,322 shs
• Market Capitalization: $1.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $76.00
• Consensus Rating: Buy

ASLAN Pharmaceuticals Stock Analysis - MarketRank™

ASLAN Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ASLAN Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ASLAN Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ASLAN Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ASLN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ASLAN Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ASLAN Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ASLN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added ASLAN Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.69% of the stock of ASLAN Pharmaceuticals is held by insiders.

Percentage Held by Institutions

58.82% of the stock of ASLAN Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ASLN Stock Analysis - Frequently Asked Questions

How have ASLN shares performed this year?

ASLAN Pharmaceuticals' stock was trading at $4.1768 at the beginning of 2024. Since then, ASLN stock has decreased by 85.6% and is now trading at $0.60.
View the best growth stocks for 2024 here.

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) released its quarterly earnings results on Friday, August, 11th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.40) by $5.52. The firm earned $12 million during the quarter.

When did ASLAN Pharmaceuticals' stock split?

Shares of ASLAN Pharmaceuticals reverse split on the morning of Wednesday, July 3rd 2024. The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did ASLAN Pharmaceuticals IPO?

ASLAN Pharmaceuticals (ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ASLAN Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Video Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 11/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASLN
• CUSIP: N/A
• CIK: 1722926
• Web: www.aslanpharma.com
• Phone: 65-6817-9598
• Fax: 65-6225-2419
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $76.00
• High Stock Price Target: $80.00
• Low Stock Price Target: $72.00
• Potential Upside/Downside: +12,566.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($21.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-44,220,000.00
• Net Margins: N/A
• Pretax Margin: -290.83%
• Return on Equity: -8,454.87%
• Return on Assets: -121.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $12 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.50) per share
• Price / Book: -0.09

Miscellaneous

• Outstanding Shares: 2,044,000
• Free Float: 1,948,000
• Market Cap: $1.23 million
• Optionable: Optionable
• Beta: 1.40